Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Weight Loss and Glucose Tolerance in Obese T2D
NCT03991299Phase 2Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in obesity, type 2 diabetes mellitus (T2DM) and prediabetes, sponsored by Vanderbilt University Medical Center. Primary endpoint: Change in Body Weight at 6 months. Started Apr 2021; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT03991299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991299.